Bearz A et al. Phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses. ASCO 2022;Abstract 9070.
Cameron LB et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1(1):CD013453. Abstract
Camidge DR. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J Thorac Oncol 2021;16(4):528-31. Abstract
Camidge DR. The magic of ADAURA? J Thorac Oncol 2022;17(3):348-50. Abstract
Chazan G. Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridization discordant ALK test results. Intern Med J 2021;51(8):1355-6. Abstract
Dagogo-Jack I et al. Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies. J Thorac Oncol 2022;18(1):67-78. Abstract
Dagogo-Jack I, Piotrowska Z. There is no unmet need for another programmed cell death protein-1 or programmed death-ligand 1 inhibitor for metastatic NSCLC. J Thorac Oncol 2022;17(10):1171-4. Abstract
Dziadziuszko R et al. Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial. Clin Cancer Res 2022;28(9):1800-8. Abstract
Hotta K et al. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open 2022;7(4):100527. Abstract
Itchins M et al. ALKternate: A proof of concept study in ALK-rearranged NSCLC alternating lorlatinib with crizotinib after disease progression. IASLC 2021;Abstract P47.12.
Itchins M et al. Dynamic circulating tumor DNA interim results from the ALKternate clinical trial. IASLC 2021;Abstract P24.03.
Jiang J et al. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: Systematic review and network meta-analysis. BMJ Open 2022;12(9):e060782. Abstract
Kuang S, Leighl NB. Lorlatinib in ALK-rearranged lung cancer. Cancer Cell 2021;39(11):25-7. Abstract
Marmarelis ME et al. Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC registry study. ASCO 2022;Abstract 9077.
Mazieres J et al. Patient-reported outcomes for the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 2022;174:146-56. Abstract
McLean L et al. Immunotherapy in oncogene addicted non-small cell lung cancer. Transl Lung Cancer Res 2021;10(6):2736-51. Abstract
Mok T et al. Outcomes according to ALK status determined by central immunohistochemistry or fluorescence in situ hybridization in patients with ALK-positive NSCLC enrolled in the phase 3 ALEX study. J Thorac Oncol 2021;16(2):259-68. Abstract
Nagasaka M, Ou SHI. Lorlatinib should be considered as the preferred first-line option in patients with advanced ALK-rearranged NSCLC. J Thorac Oncol 2022;16(4):528-36. Abstract
Shiba-Ishii A et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer 2022;3(6):710-22. Abstract
Simons EA et al. Pregnancy and pathways to motherhood in oncogene-driven lung cancer: A single institution experience. Clin Lung Cancer 2023;24(2):e55-9. Abstract
Solomon JJ et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2022;11(1):87-96. Abstract